Peter Buggisch

13.0k citations

195 papers · 5.1k · 1 hit paper · h-index 29

Impact in

Hepatology top 0.2%
- Hepatitis C virus research
- Hepatitis Viruses Studies and Epidemiology
Epidemiology top 0.5%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment

Papers in

Hepatology 161
- Hepatitis C virus research 147
- Liver Diseases and Immunity 15
- Liver Disease and Transplantation 10
Epidemiology 95
- Liver Disease Diagnosis and Treatment 61
- Hepatitis B Virus Studies 49

Co-authors: Thomas Berg (66 shared papers)Stefan Zeuzem (51 shared papers)Christoph Sarrazin (38 shared papers)Heiner Wedemeyer (46 shared papers)Wolff Schmiegel (5 shared papers)R. Pichlmayr (2 shared papers)Jens Witte (2 shared papers)G. Riethmüller (2 shared papers)
Journals: Journal of Hepatology (69 papers)Liver International (11 papers)Hepatology (10 papers)Gastroenterology (8 papers)PLoS ONE (7 papers)
Partner nations: Germany United States France

In The Last Decade

Peter Buggisch

179 papers receiving 4.9k citations

Peter Buggisch's Hit Papers

align trajectories log scale

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma 1994 · 532 citations

Peers

Countries citing papers authored by Peter Buggisch

Since Specialization

Citations

This map shows the geographic impact of Peter Buggisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Buggisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Buggisch more than expected).

Fields of papers citing papers by Peter Buggisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Buggisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Buggisch. The network helps show where Peter Buggisch may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Buggisch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Buggisch Line = papers co-authored together Peter Buggisch links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 195 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma The Lancet ·G. Riethmüller, Rudolf Gruber, E. Schneider-Gädicke, Günter Schlimok, Jens Witte, R. Raab, R. Pichlmayr, H. Pichlmaier, Wolff Schmiegel, Peter Buggisch, K. Höffken, H. Hirche, R. Pichimayr, German Cancer Aid –A Study Group Hit paper breakdown →	1994	532
2	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Gastroenterology ·Marion G. Peters, Hie‐Won Hann, Paul Martin, E. Jenny Heathcote, Peter Buggisch, R Rubin, Marc Bourlière, Kris V. Kowdley, Christian Trépo, DF Gray, Mark Sullivan, K. Kleber, Ramin Ebrahimi, S. Xiong, Carol Brosgart	2003	454
3	Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. Journal of Clinical Oncology ·G. Riethmüller, E Holz, Günter Schlimok, Wolff Schmiegel, R. Raab, K. Höffken, Rudolf Gruber, I. Funke, H. Pichlmaier, H. Hirche, Peter Buggisch, Jens Witte, R. Pichlmayr	1998	427
4	Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin Gastroenterology ·Thomas Berg, Michael Wagner, Samer Nasser, Christoph Sarrazin, Tobias Heintges, Tilman Gerlach, Peter Buggisch, Tobias Goeser, J. Rasenack, Gerd R. Pape, Wolfgang E. Schmidt, B. Kallinowski, Hartwig Klinker, Ulrich Spengler, Peter Martus, U. Alshüth, Stefan Zeuzem	2006	379
5	Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology ·Karsten Wursthorn, Marc Lütgehetmann, Maura Dandri, Tassilo Volz, Peter Buggisch, Bernhard Zöllner, Thomas Longerich, Peter Schirmacher, Frauke Metzler, M Zankel, C Fischer, Graeme Currie, Carol Brosgart, Joerg Petersen	2006	361
6	Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues Hepatology ·Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Katja Deterding, Jörg Petersen, Peter Buggisch, Andreas Erhardt, D Hüppe, Kerstin Stein, Jörg Trojan, Christoph Sarrazin, Wulf O. Böcher, Ulrich Spengler, Hermann E. Wasmuth, Jurrien G.P. Reinders, Bernd Möller, Peter R. Rhode, Heinz‐Hubert Feucht, Bertram Wiedenmann, Thomas Berg	2009	276
7	Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock Critical Care Medicine ·G. Kreymann, SEBASTIAN GROSSER, Peter Buggisch, CLAUS GOTTSCHALL, S. Matthäei, Heiner Greten	1993	208
8	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study Hepatology ·Johannes Wiegand, Peter Buggisch, Wulf O. Boecher, Stefan Zeuzem, Cornelia M. Gelbmann, Thomas Berg, Wolfgang Kauffmann, B. Kallinowski, Markus Cornberg, Elmar Jaeckel, Heiner Wedemeyer, Michael P. Manns	2006	162
9	Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis? The American Journal of Gastroenterology ·Elke Hennes, Ye Htun Oo, Christoph Schramm, U Denzer, Peter Buggisch, Christiane Wiegard, Stephan Kanzler, Marcus Schuchmann, Wulf O. Boecher, Peter R. Galle, David Adams, Ansgar W. Lohse	2008	141
10	Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection Liver International ·Patrick Marcellin, David Wong, William Sievert, Peter Buggisch, Jörg Petersen, Robert Flisiak, Michael P. Manns, Kelly Kaita, Zahari Krastev, Samuel S. Lee, Andrea L. Cathcart, Gerald Crans, Marjoleine Op den Brouw, Belinda Jump, Anuj Gaggar, John F. Flaherty, Marı́a Buti	2019	106
11	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study Journal of Hepatology ·Jörg Petersen, Vlad Ratziu, Marı́a Buti, Harry L.A. Janssen, Ashley Brown, Pietro Lampertico, J Schollmeyer, Fabien Zoulim, Heiner Wedemeyer, Martina Sterneck, Thomas Berg, Christoph Sarrazin, Marc Lütgehetmann, Peter Buggisch	2011	99
12	Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals Journal of Hepatology ·P. Cacoub, Marc Bourlière, Jann Lübbe, N. Dupin, Peter Buggisch, Geoffrey Dusheiko, Christophe Hézode, O Picard, Ramón M. Pujol, Siegfried Segaert, Bing Thio, Jean‐Claude Roujeau	2011	98
13	The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C Hepatology ·Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, Patrick Marcellin, D. Séréni, Hartwig Klinker, Christophe Moreno, Jean‐Pierre Zarski, Yves Horsmans, Hongmei Mo, Sarah Arterburn, Steven Knox, David Oldach, John G. McHutchison, Michael P. Manns, Graham R. Foster	2011	97
14	Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions Journal of Hepatology ·David M. Burger, David Back, Peter Buggisch, Marı́a Buti, Antonio Craxı̀, Graham R. Foster, Hartwig Klinker, Dominique Larrey, И. Г. Никитин, Stanislas Pol, Massimo Puoti, Manuel Romero‐Gómez, Heiner Wedemeyer, Stefan Zeuzem	2012	95
15	Acoustic radiation force impulse imaging for non‐invasive assessment of liver fibrosis in chronic hepatitis B Journal of Viral Hepatitis ·Mireen Friedrich-Rust, Peter Buggisch, Robert J. de Knegt, V. Dries, Yuxin Shi, Katrin Matschenz, M. Schneider, Eva Herrmann, J. Petersen, Falko Schulze, Stefan Zeuzem, Christoph Sarrazin	2012	68
16	Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice? Addiction ·Stefan Christensen, Peter Buggisch, Stefan Mauss, Klaus H.W. Böker, Eckart Schott, Hartwig Klinker, Tim Zimmermann, Bernd Weber, Jens Reimer, Yvonne Serfert, Heiner Wedemeyer	2018	64
17	Triple Therapy With Amantadine in Treatment–Naive Patients With Chronic Hepatitis C: A Placebo–Controlled Trial Hepatology ·Thomas Berg, Bernd Kronenberger, Holger Hinrichsen, Tilman Gerlach, Peter Buggisch, Eva Herrmann, Ulrich Spengler, Tobias Goeser, Samer Nasser, Karsten Wursthorn, Gerd R. Pape, Uwe Hopf, Stefan Zeuzem	2003	57
18	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C Journal of Hepatology ·Michael P. Manns, Stefan Zeuzem, Ajit Sood, Yoav Lurie, Markus Cornberg, Hartwig Klinker, Peter Buggisch, Martin Rössle, Holger Hinrichsen, I Merican, Yaron Ilan, Stefan Mauss, Saif Abu‐Mouch, A Horban, Thomas Müller, Christoph Welsch, Rongdean Chen, Rab Faruqi, Lisa D. Pedicone, Heiner Wedemeyer	2011	44
19	Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C Journal of Hepatology ·Peter Buggisch, Johannes Vermehren, Stefan Mauss, Rainer Günther, Eckart Schott, Anita Pathil, Klaus Boeker, Tim Zimmermann, G Teuber, Heike-Pfeiffer Vornkahl, Karl‐Georg Simon, Claus Niederau, Heiner Wedemeyer, Stefan Zeuzem	2017	43
20	Hepatitis D virus‐specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa‐treatment Liver International ·(unknown), Cihan Yurdaydın, Kalliopi Zachou, Peter Buggisch, Wolf Peter Hofmann, Jerzy Jaroszewicz, Verena Schlaphoff, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, (unknown)	2011	42

About Peter Buggisch

Peter Buggisch is a scholar working on Hepatology, Epidemiology, Rheumatology, Infectious Diseases and Genetics, having authored 195 papers that have together received 5.1k indexed citations. Recurring topics across this work include Hepatitis C virus research (147 papers), Liver Disease Diagnosis and Treatment (61 papers), Hepatitis B Virus Studies (49 papers), Systemic Lupus Erythematosus Research (25 papers), Liver Diseases and Immunity (15 papers), HIV/AIDS drug development and treatment (13 papers), Liver Disease and Transplantation (10 papers) and Chronic Lymphocytic Leukemia Research (8 papers). The work is most often cited by research in Hepatology (2.9k citations), Epidemiology (2.7k citations), Oncology (581 citations), Infectious Diseases (378 citations) and Immunology (427 citations). Peter Buggisch has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Thomas Berg, Stefan Zeuzem, Christoph Sarrazin, Heiner Wedemeyer, Wolff Schmiegel, R. Pichlmayr, Jens Witte, G. Riethmüller, Rudolf Gruber and H. Pichlmaier. Their work appears in journals such as Journal of Hepatology, Liver International, Hepatology, Gastroenterology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Peter Buggisch

Impact in

Papers in i

In The Last Decade

Peter Buggisch

Peter Buggisch's Hit Papers

Peers

Countries citing papers authored by Peter Buggisch

Fields of papers citing papers by Peter Buggisch

All Works

About Peter Buggisch

Explore authors with similar magnitude of impact

Papers in